Do you want to read an article? Please log in or register.
Improvements in health-related quality of life in people with cystic fibrosis ≥6 years of age treated with vanzacaftor/tezacaftor/deutivacaftor
Pulmonary Fibrosis
Related content
Pulmonary Fibrosis
LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis
J Cyst Fibros
Vega-Hernandez G, MacGregor G, Wilfin A, Adams F, Haugh C, Baxter CA, Wöhling H, Clarke SL, Charman SC, Carr SB
doi: 10.1016/j.jcf.2025.04.012
Further Publications
Sweat chloride and lung function responses to elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies
Lancet Respir Med
Burgel PR, Da Silva J, Girodon E, Durieu I, Reynaud-Gaubert M, Murris-Espin M, Chiron R, Grenet D, Ramel S, Mely L, Hamidfar R, Douvry B, Houdouin V, Audousset C, Macey J, Mittaine M, Weiss L, Cosson L, Danner-Boucher I, Reix P, Baravalle M, Burnet E, Sermet-Gaudelus I, Martin C, Paillasseur JL, French Cystic Fibrosis Reference Network study group
doi: 10.1016/S2213-2600(25)00190-0
ARDS
Long-Term Health-Related Quality of Life Following Survival of Acute Respiratory Distress Syndrome and Extracorporeal Membrane Oxygenation Due to COVID-19
J Clin Med
Hermann M, Filipsky R, Bukowski N, Gerger G, Hermann A, Krenn K, Teufel A, Kimberger O, Laxar D, Maleczek M, Schaden E, Wiegele M, Willschke H, Tiboldi A
doi: 10.3390/jcm14103358
Pulmonary Fibrosis
The Effects of Progressive Muscle Relaxation on Mental Health and Sleep Quality in Adults with Cystic Fibrosis: A Randomized Controlled Trial
J Clin Med
Maritescu A, Pescaru CC, Crisan AF, Stoicescu ER, Oancea C, Iacob D
doi: 10.3390/jcm14082807
Further Publications
Longitudinal trajectories of health-related quality of life and their predictors among community-dwelling older adults
Sci Rep
Oshima R, Ohashi Y, Iwane T, Tamada Y, Kinoshita F, Ito T, Okumura Y, Mikami T, Itoh K, Murashita K, Nakatochi M
doi: 10.1038/s41598-025-30307-8
RECOMMENDED
Pulmonary Fibrosis
BEAT-CF (Bayesian Evidence Adaptive Treatment for people with Cystic Fibrosis): description of a prospective cohort for nested studies in cystic fibrosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Respir Med
Fathima P, Pan E, Marsh J, Newall N, Meares T, McLeod C, Shanthikumar S, Jaffe A, Tai A, Ward N, Sivam S, Selvadurai H, Schultz A, Snelling T
doi: 10.1016/j.rmed.2025.108080
RECOMMENDED
Pulmonary FibrosisBronchi
Effect of elexacaftor-tezacaftor-ivacaftor on bronchial dilatations in adolescents with cystic fibrosis: a multicentre prospective observational study
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med
Sermet-Gaudelus I, Letierce A, Berteloot L, Bonnel AS, Chen Y, Makani P, Kelly-Aubert M, Kanoun F, Penalva L, Bouleghem N, Bihouee T, Bui S, Corvol H, Houdouin V, Mittaine M, Tatopoulos A, Weiss L, Wizla N, Kapel N, Bessou A, Tiddens HAWM, Caudri D, Reix P, Marguet C, MODUL-CF study group
doi: 10.1016/S2213-2600(25)00248-6
RECOMMENDED
Pulmonary FibrosisRespiratory Tract Infection
Real -World impact of previous exposure to CFTR modulators on clinical parameters and chronic sinus disease in people with cystic fibrosis on elexacaftor-tezacaftor-ivacaftor
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Holtzlander M, Lind M, Eisner M, Gushue C, Palacios S, Kotha K, Imran S, McCoy K, Sheikh S
doi: 10.1016/j.rmed.2025.108274
RECOMMENDED
Pulmonary Fibrosis
Severe hepatotoxicity is uncommon following the introduction of Elexacaftor/Tezacaftor/Ivacaftor: A real-world two-years follow-up study of the Danish cystic fibrosis cohort
★ 1
Recommended by
Dr Martin Frey, Faculty Member
J Cyst Fibros
Højte C, Olsen MF, Faurholt-Jepsen D, Jørgensen MH, Pressler T, Leo-Hansen C, Bryrup T, Jeppesen M, Olesen HV, Petersen J, Katzenstein TL, Nielsen BU, Skov M, TransformCF Study Group
doi: 10.1016/j.jcf.2025.08.008